

Natera selected for ctDNA study, 12/17

December 2017—Natera announced a second research collaboration with Denmark's Aarhus University utilizing the company's research use only technology to evaluate ctDNA as a useful biomarker for detecting minimal residual disease, treatment response, and disease recurrence in colorectal cancer patients. (The university will also use the Signatera technology in a bladder cancer study.)

This second study will evaluate 130 patients with stage I-III colorectal cancer previously treated with surgery and adjuvant chemotherapy and then monitored longitudinally with blood samples drawn approximately every three months for up to 36 months. Sequencing data from each individual's tumor will be provided by Aarhus University and analyzed using the Signatera proprietary bioinformatics pipeline, resulting in custom ctDNA assays designed for each individual. The objective of the study is to determine the relationship between postsurgical ctDNA levels, minimal residual disease, disease relapse, and adjuvant therapeutic response. Study results are expected in 2018, which will help support the launch of Signatera in the clinical setting.

[Natera](#), 844-778-4700